Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: A randomized placebo-controlled clinical trial

Nutrition

Volumn 28, Issue 9, 2012, Pages 892-895

  Sayyah, Mehdi ^a   Olapour, Alireza ^a   Saeedabad, Yashar shahhosseini ^b   Yazdan Parast, Rezvan ^b   Malayeri, Alireza ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Imam Khomeini General Hospital   (Iran)

Author keywords

Clinical trial; Obsessive compulsive disorder; Zinc

Indexed keywords

FLUOXETINE; OXAZEPAM; PLACEBO; ZINC SULFATE;

ADULT; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADMINISTRATION, ORAL; ADULT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TRACE ELEMENTS; TREATMENT OUTCOME; ZINC; ZINC SULFATE;

EID: 84864499815     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2011.11.027     Document Type: Article

References (28)

1. Nowak G., Szewczyk B. Mechanisms contributing to antidepressant zinc action. Pol J Pharmacol 2002, 54:587-592.
2. Takeda A. Movement of zinc and its functional significance in the brain. Brain Res Bull 2000, 34:137-148.
3. Barañano D.E., Ferris C.D., Snyder S.H. Atypical neural messengers. Trends Neurosci 2001, 24:99-106.
4. Choi D.W., Koh J.Y. Zinc and brain injury. Annu Rev Neurosci 1998, 21:347-375.
5. Frederickson C.J., Klitenick M.A., Manton W.I., Kirkpatrick J.B. Cytoarchitectonic distribution of zinc in the hippocampus of man and rat. Brain Res 1983, 273:335-339.
6. Baltaci A.K., Mogulkoc R. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc. Acta Biol Hung 2007, 58:335-343.
7. Frederickson C.J., Won Suh S., Silva D., Frederickson C.J., Thompson R.B. Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 2000, 130:1471S-14783.
8. Peters S., Koh J.Y., Choi D.W. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science 1987, 236:589-593.
9. Bancila V., Nikonenko I., Dunant Y., Bloc A. Zinc inhibits glutamate release via activation of presynaptic K channels and reduces ischaemic damage in rat hippocampus. J Neurochem 2004, 90:1243-1250.
10. Harrison N., Gibbons S.J. Zn: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology 1994, 33:935-952.
11. Smart T.G., Xie X., Krishek B.J. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Prog Neurobiol 1994, 42:393-441.
12. Ilouz R., Kaidanovich O., Gurwitz D., Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun 2002, 295:102-106.
13. Gould T.D., Picchini A.M., Einat H., Manji H.K. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 2006, 7:1399-1409.
14. Rosa A.O., Lin J., Calixto J.B., Santos A.R., Rodrigues A.L.S. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 2003, 144:87-93.
15. Bediz C.S., Baltaci A.K., Mogulkoc R., Oztekin E. Zinc supplementation ameliorates electromagnetic field-induced lipid peroxidation in the rat brain. Tohoku J Exp Med 2006, 208:133-140.
16. Baltaci A.K., Mogulkoc R., Bediz C.S., Pekel A. Effects of zinc deficiency and pinealectomy on cellular immunity in rats infected with Toxoplasma gondii. Biol Trace Elem Res 2005, 104:47-56.
17. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) 2000, American Psychiatric Association, American Psychiatric Press, Washington, DC.
18. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
19. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
20. Starck G., Ljungberg M., Nilsson M., Jonsson L., Lundberg S., Ivarsson T., et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 2008, 115:1051-1062.
21. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005, 58:424-428.
22. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007, 17:761-767.
23. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004, 174:530-538.
24. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007, 62:835-838.
25. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008, 165:335-341.
26. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009, 29:51-55.
27. Goodman W., Price L., Rasmussen S., Mazure C., Fleischman R., Hill C. The Yale-Brown Obsessive-Compulsive Scale I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
28. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2000. Available at: Accessed 2008. http://www.wma.net.